HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients

No abstract is available for this paper.

• Publication year

  2006

• Venue

  AIDS (London)

• Publication date

  2006-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.aids.0000238408.82947.09PMID 16868443
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again.

  2006influential reference
• Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

  2005influential reference
• Clinical heterogeneity of drug hypersensitivity.

  2005cited by this paper
• Serious Adverse Cutaneous and Hepatic Toxicities Associated With Nevirapine Use by Non–HIV-Infected Individuals

  2004cited by this paper
• Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

  2004cited by this paper
• Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.

  2004cited by this paper
• A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients*

  2003cited by this paper
• Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

  2002cited by this paper
• Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones.

  2001cited by this paper
• Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.

  2001cited by this paper
• Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine.

  2001cited by this paper
• From the Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.

  2001cited by this paper
• HIV and drug allergy

  2001cited by this paper
• Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype.

  2001cited by this paper
• The role of nevirapine in the treatment of HIV-1 disease

  2001cited by this paper
• Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV‐Positive Patients Treated With HAART

  2001cited by this paper
• Degeneracy and additional alloreactivity of drug-specific human αβ+ T cell clones

  2001cited by this paper
• Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.

  2000cited by this paper
• Frequency of Cutaneous Reactions on Rechallenge with Nevirapine and Delavirdine

  2000cited by this paper
• The distribution of HLA class II haplotypes reveals that the Sardinian population is genetically differentiated from the other Caucasian populations.

  2000cited by this paper
• Allele-unrestricted presentation of lidocaine by HLA-DR molecules to specific alphabeta+ T cell clones.

  1998cited by this paper
• HLA polymorphisms in Italian bone marrow donors: a regional analysis.

  1998cited by this paper
• Allele-unrestricted presentation of lidocaine by HLA-DR molecules to specific αβ F T cell clones

  1998cited by this paper
• High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection.

  1995cited by this paper
• HLA structure of the Sardinian population: a haplotype study of 551 families.

  1992cited by this paper
• A haplotype study of HLA complex with special reference to the HLA-DR series and to Bf. C2 and glyoxalase I polymorphisms.

  1978cited by this paper

• The association between the number of HLA risk alleles and drug allergy and its implications for HLA screening – a case-control study

  2025cites this paper
• Cutaneous drug reactions: classification, diagnosis, clinical and therapeutic consequences

  2025cites this paper
• Kutane Arzneimittelreaktionen: Klassifikation, Diagnostik, klinische und therapeutische Konsequenzen

  2025cites this paper
• Molecular docking to investigate HLA-associated idiosyncratic drug reactions

  2025cites this paper
• Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review

  2023cites this paper
• Delayed Drug Hypersensitivity Reactions: Molecular Recognition, Genetic Susceptibility, and Immune Mediators

  2023cites this paper
• HLA alleles associated with COVID-19 susceptibility and severity in different populations: a systematic review

  2023cites this paper
• Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions.

  2023cites this paper
• Association of Human Leukocyte Antigen Alleles and Hypersensitivity of Efavirenz/Nevirapine in HIV-Infected Chinese Patients

  2022cites this paper
• Human Leukocyte Antigen (HLA) Testing in Pharmacogenomics.

  2022cites this paper
• The Association of HLA-B*35 and GSTT1 Genotypes and Hepatotoxicity in Thai People Living with HIV

  2022cites this paper
• Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)—Readdressing the DReSS

  2022cites this paper
• The Immunogenetics of Cutaneous Drug Reactions.

  2022cites this paper
• Drug-Induced Hypersensitivity Syndrome (DIHS)/ Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis.

  2022cites this paper
• Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions

  2021cites this paper
• Genetics of Severe Cutaneous Adverse Reactions

  2021cites this paper
• Immunogenetic features of HIV-infection and allergy comorbidity

  2021cites this paper
• Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience

  2020cites this paper
• Spanish Guidelines for Diagnosis, Management, Treatment and Prevention of DRESS syndrome.

  2020cites this paper
• Genetic variants associated with T cell–mediated cutaneous adverse drug reactions: A PRISMA‐compliant systematic review—An EAACI position paper

  2020cites this paper
• Spanish Guidelines for Diagnosis, Management, Treatment and Prevention of DRESS syndrome Brief running title: DRESS syndrome Spanish guidelines

  2020cites this paper
• Viral reactivation and outcomes in drug reaction with eosinophilia and systemic symptoms (DRESS)

  2020cites this paper
• Revisiting the association of HLA alleles and haplotypes with CYP21A2 mutations in a large cohort of patients with congenital adrenal hyperplasia.

  2019influential citation
• Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.

  2019cites this paper
• Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis

  2019cites this paper
• Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity

  2019cites this paper
• Pharmacogenetic Markers: A Path toward Individualized HIV Therapy.

  2019influential citation
• HIV pharmacogenetics and pharmacogenomics: From bench to bedside

  2019cites this paper
• Genetic testing for prevention of severe drug-induced skin rash.

  2019cites this paper
• Pharmacogenomics and Cutaneous Adverse Drug Reactions

  2018cites this paper
• Cutaneous Adverse Drug Reactions in Human Immunodeficiency Virus Infection

  2018cites this paper
• Pharmacogenetics of Adverse Drug Reactions.

  2018cites this paper
• HLAs: Key regulators of T‐cell‐mediated drug hypersensitivity

  2018cites this paper
• Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention

  2018cites this paper
• An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity

  2018cites this paper
• Adverse Cutaneous Drug Eruptions: Review of Immunology, Pathogenesis, and Pharmacogenomics With Focus on HIV and TEN

  2018cites this paper
• Docking simulations between drugs and HLA molecules associated with idiosyncratic drug toxicity.

  2017cites this paper
• Antibiotic allergy testing and its impact on antimicrobial stewardship

  2017cites this paper
• HLA Association with Drug-Induced Adverse Reactions

  2017cites this paper
• Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles

  2017cites this paper
• Genetic Predictors of Drug Hypersensitivity.

  2017cites this paper
• Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions

  2017cites this paper
• Severe Delayed Drug Reactions: Role of Genetics and Viral Infections.

  2017cites this paper
• Pharmacogenomics of off‐target adverse drug reactions

  2017cites this paper
• Genetics of Adverse Drug Reactions

  2017cites this paper
• Pharmacogenetic considerations in the treatment of HIV.

  2017cites this paper
• Current Progress in the Pharmacogenetics of Infectious Disease Therapy

  2017cites this paper
• A Modern View of the Pathogenesis of Allergy with Drug Etiology

  2016cites this paper
• Association between HLA-B alleles and nevirapine-induced allergies among Indonesian HIV patients

  2016cites this paper
• Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity

  2016cites this paper
• The impact of antiretroviral therapy used in pregnancy on the health of HIV-positive women

  2016influential citation
• Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation

  2016cites this paper
• A pharmacist's role in the individualization of treatment of HIV patients.

  2016cites this paper
• HLA and Delayed Drug-Induced Hypersensitivity

  2016cites this paper
• In silico Analysis of Interactions between Nevirapine-related Compounds, HLA-B*14:02 and T-cell Receptor

  2016cites this paper
• Implications of Pharmacogenetics for Antimicrobial Prescribing

  2016cites this paper
• The immunopathogenesis of drug hypersensitivity

  2016cites this paper
• T cell-mediated hypersensitivity reactions to drugs.

  2015cites this paper
• Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.

  2015cites this paper
• Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review

  2015cites this paper
• Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms

  2015influential citation
• Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.

  2015cites this paper
• The multiple roles of hla in hiv immunity and treatment

  2015cites this paper
• Advances in the Pharmacogenomics of Adverse Drug Reactions

  2015cites this paper
• Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities.

  2015cites this paper
• Individualization of antiretroviral therapy - Pharmacogenomic aspect

  2015cites this paper
• HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity: a systematic review of the literature and meta-analysis

  2015cites this paper
• Cytochrome P450s: mechanisms and biological implications in drug metabolism and its interaction with oxidative stress.

  2015cites this paper
• Role of dermatology in pharmacogenomics: drug-induced skin injury.

  2015cites this paper
• Frequencies of immune hypersensitivity reaction-associated HLA class I alleles in healthy South African Indian and mixed ancestry populations determined by a novel real-time PCR assay.

  2014cites this paper
• Severe cutaneous adverse reactions: impact of immunology, genetics, and pharmacology.

  2014cites this paper
• HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity

  2014cites this paper
• HLA Associations and Clinical Implications in T-Cell Mediated Drug Hypersensitivity Reactions: An Updated Review

  2014cites this paper
• Genotyping for Severe Drug Hypersensitivity

  2014cites this paper
• Mechanisms of Adverse Drug Reactions

  2014cites this paper
• Pharmacogenetic markers of severe cutaneous adverse drug reactions.

  2014cites this paper
• Human leukocyte antigen (HLA) pharmacogenomic tests: potential and pitfalls.

  2014cites this paper
• Pharmacogenomics of antimicrobial agents.

  2014cites this paper
• Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study

  2014cites this paper
• Investigation of immunogenetic risk factors for carbamazepine-induced hypersensitivity reactions

  2014cites this paper
• Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

  2014cites this paper
• Pharmacogenetics of antiretroviral therapy

  2014cites this paper
• Immunogenetics of allergic reactions to drugs

  2014cites this paper
• HLA and the Pharmacogenomics of Drug Hypersensitivity

  2014cites this paper
• Insilico study of HLA-DRB1*0101 allele association in Nevirapine (NVP) induced hypersensitivity among Indian HIV-Infected Population

  2014cites this paper
• Role of Human Leukocyte Antigens on Severe Cutaneous Drug Reactions

  2013cites this paper
• The Pharmacogenetics of HIV Treatment: A Practical Clinical Approach

  2013cites this paper
• Associations Between HLA-DRB1*0102, HLA-B*5801, and Hepatotoxicity During Initiation of Nevirapine-Containing Regimens in South Africa

  2013cites this paper
• Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population

  2013cites this paper
• NEVIRAPINE HEPATOTOXICITY: IMPLICATIONS OF RISK FACTORS

  2013cites this paper
• Pharmacogenomics of adverse drug reactions

  2013cites this paper
• Human leukocyte antigen-associated drug hypersensitivity.

  2013cites this paper
• บทบาทของ Human Leukocyte Antigen กับการแพ้ยาทางผิวหนังชนิดรุนแรง

  2013cites this paper
• TABLE 1. Univariate and Multivariate Associations Between HLA Types and Nevirapine-Associated Hepatotoxicity*†

  2013cites this paper
• Genetic testing for prevention of severe drug-induced skin rash.

  2013cites this paper
• Testing for drug hypersensitivity syndromes.

  2013cites this paper
• [The associations between idiosyncratic adverse drug reactions and HLA alleles and their underlying mechanism].

  2013cites this paper
• HIV Pharmacogenetics and Pharmacogenomics

  2013cites this paper
• Hepatotoxicity of Antiviral Agents

  2013cites this paper
• Antimicrobial stewardship's new weapon? A review of antibiotic allergy and pathways to 'de-labeling'.

  2013cites this paper